|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:awarded
|
gptkb:Princess_of_Asturias_Award_for_Technical_and_Scientific_Research_(2021)
|
|
gptkbp:CEO
|
gptkb:Uğur_Şahin
|
|
gptkbp:chairman
|
gptkb:Helmut_Jeggle
|
|
gptkbp:collaboratedWith
|
gptkb:Pfizer
gptkb:Fosun_Pharma
|
|
gptkbp:country
|
gptkb:Germany
|
|
gptkbp:developedBy
|
vaccine
|
|
gptkbp:focusesOn
|
infectious diseases
immunotherapy
mRNA therapeutics
|
|
gptkbp:foundedBy
|
gptkb:Uğur_Şahin
gptkb:Özlem_Türeci
gptkb:Christoph_Huber
|
|
gptkbp:foundedYear
|
2008
|
|
gptkbp:headquartersLocation
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BioNTech SE
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US09075V1026
|
|
gptkbp:legalForm
|
Societas Europaea
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:mainLanguage
|
gptkb:German
English
|
|
gptkbp:marketCap
|
over $20 billion (2023)
|
|
gptkbp:netIncome
|
€930 million (2023)
|
|
gptkbp:notableEvent
|
Emergency Use Authorization for COVID-19 vaccine in December 2020
First mRNA COVID-19 vaccine approved worldwide
IPO in October 2019
|
|
gptkbp:notableProduct
|
gptkb:BNT162b2
gptkb:Comirnaty
|
|
gptkbp:numberOfEmployees
|
over 3,000
|
|
gptkbp:parentCompany
|
gptkb:BioNTech_Group
|
|
gptkbp:researchInterest
|
gene therapy
antibodies
personalized cancer vaccines
small molecule immunomodulators
|
|
gptkbp:revenue
|
€3.8 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:BNTX
|
|
gptkbp:subsidiary
|
gptkb:BioNTech_US_Inc.
|
|
gptkbp:tradedOn
|
gptkb:Frankfurt_Stock_Exchange:22UA
gptkb:NASDAQ:BNTX
|
|
gptkbp:website
|
https://biontech.com
|
|
gptkbp:bfsParent
|
gptkb:BioNTech
|
|
gptkbp:bfsLayer
|
5
|